Enovis on Track for $1 Billion Recon Business

Orthopedic Market Growth

Enovis’ reconstructive segment grew 66% on a reported basis and 7% pro forma in the first quarter of 2024. The company’s aggressive M&A strategy and consistently above-market organic growth have it on the cusp of $1 billion in annual joint replacement sales.

The company’s evolution to a balanced portfolio with more attractive...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us